£26m+ for spin-out behind new liver treatment
Breakthrough may replace need for transplants
Advanced liver damage could be treated and repaired instead of requiring a transplant thanks to a University of Edinburgh spinout company.
Resolution Therapeutics is developing cell treatments to repair organ damage – including end-stage chronic liver disease – based on a decade of research at the University’s Centre for Regenerative Medicine.
It has received funding of £26.6 million from Syncona, a specialist healthcare investment company. The investment is expected to enable Resolution to gain early clinical data for its first product.
The new biopharmaceutical company is developing macrophage cell therapies. Macrophages are immune system cells involved in responses to injury, including the wound-healing process. Resolution is exploiting the ability of macrophages to stimulate organ repair following damage caused by disease.
Resolution’s first programme is an engineered macrophage to treat patients with compensated liver cirrhosis – where the liver is badly damaged but still functioning.
Cirrhosis is caused by long-term damage to the liver. More than 4,000 people a year in the UK die from cirrhosis with around 700 people needing a liver transplant.
There are currently no therapies available and patients are at risk of progressing to decompensated cirrhosis, where the liver can no longer cope and the patient needs a transplant.
Professor Stuart Forbes, director of the Centre for Regenerative Medicine at the University of Edinburgh, and his research team have been working for a decade on the role of macrophages in organ repair, with funding from the Medical Research Council.